Pharma News

Due shortage of doctors in public healthcare facilities, the Odisha government has permitted pharmacists to treat minor ailments and dispense drugs for certain diseases in hospitals.

Pfizer Inc and BioNTech SE announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countries to one billion.

Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies is planning to launch Cephalosporin products soon. Company has acquired a facility in Mehsana, Gujarat. Investment in Cephalosporin plant for Rs 30 crore including Croreicapacity expansion and modernisation of the facility. Acquisition and further capex will be funded from internal accruals. Company expects commercial operations from March 2022. The plant is expected to contribute sales of around Rs 150 crore in the next 3 years.

Glenmark Pharmaceuticals Ltd has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately $12.0 million*.

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India. The PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients. A total of 1083 patients were enrolled in the prospective, open label, multicentre, single arm study.

RELIEF THERAPEUTICS Holding SA a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that it has received scientific advice from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) relating to its lead investigational drug, RLF-100(TM) (aviptadil), for the treatment of respiratory deficiency due to severe COVID-19.

Myovant Sciences and Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022 for this sNDA under the Prescription Drug User Fee Act (PDUFA).

Galderma announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Aging Medicine World Congress (AMWC), taking place in Monaco and virtually on September 16–18, 2021.